Hims & Hers Health, Inc. (NYSE:HIMS) Receives $20.71 Average Price Target from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) has earned an average recommendation of "Hold" from the sixteen research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $20.71.

Several equities analysts have commented on the stock. TD Cowen reissued a "buy" rating and issued a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a report on Wednesday, November 6th. Piper Sandler restated a "neutral" rating and set a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a "buy" rating and a $24.00 target price for the company. Finally, Bank of America lowered Hims & Hers Health from a "buy" rating to an "underperform" rating and cut their target price for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,345 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the transaction, the insider now directly owns 159,796 shares of the company's stock, valued at $2,341,011.40. This trade represents a 1.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christiane Pendarvis sold 7,000 shares of the business's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the sale, the director now owns 23,917 shares in the company, valued at $362,342.55. This represents a 22.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,056,183 shares of company stock worth $21,501,682 in the last quarter. Company insiders own 17.71% of the company's stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently modified their holdings of the business. Robeco Institutional Asset Management B.V. acquired a new position in shares of Hims & Hers Health in the third quarter valued at approximately $604,000. Carnegie Investment Counsel purchased a new stake in shares of Hims & Hers Health in the third quarter valued at $5,531,000. Royce & Associates LP grew its position in shares of Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company's stock valued at $6,281,000 after purchasing an additional 49,500 shares during the period. Versor Investments LP acquired a new position in Hims & Hers Health in the third quarter valued at $634,000. Finally, International Assets Investment Management LLC purchased a new position in Hims & Hers Health during the third quarter worth about $6,790,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Up 8.9 %

Shares of Hims & Hers Health stock traded up $1.94 during mid-day trading on Thursday, hitting $23.73. The stock had a trading volume of 18,429,000 shares, compared to its average volume of 9,463,500. The firm has a market cap of $5.18 billion, a P/E ratio of 53.93 and a beta of 1.06. Hims & Hers Health has a 12-month low of $7.67 and a 12-month high of $30.44. The firm has a 50-day moving average of $20.21 and a two-hundred day moving average of $19.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.04) EPS. Sell-side analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.